Community Conversation => Transsexual talk => Male to female transsexual talk (MTF) => Topic started by: Bea1968 on May 16, 2019, 07:18:32 AM Return to Full Version
Title: Bravo device and fat transplant
Post by: Bea1968 on May 16, 2019, 07:18:32 AM
Post by: Bea1968 on May 16, 2019, 07:18:32 AM
Last night I was reading about using my own fat to augment my breasts and came across some literature about a Brava device. From what I can tell it was originally marketed as a device to enlarge breasts but was not especially well reviewed. Then a surgeon in Miami decided that even if breast expansion was temporary, they could use it to expand the breasts somewhat to allow a larger amount of fat to be transplanted. Has anyone had any experience with this device or with the fat transplant augmentation procedure?
Best regards,
Bea
Best regards,
Bea
Title: Re: Bravo device and fat transplant
Post by: KristySims on May 16, 2019, 01:05:42 PM
Post by: KristySims on May 16, 2019, 01:05:42 PM
Hey Bea! I read about this too for the same reason Wink Wink! using our own body's tissue!! So here is what I found substantial.... https://www.ncbi.nlm.nih.gov/pubmed/22261565
RESULTS:
Breast volume was unchanged between 3 and 6 months. Seventy-one of the treated women were compliant with Brava wear and had a mean augmentation volume at 12 months of 233 ml per breast compared with 134 ml per breast in published series without Brava (p < 0.00001). Graft survival was 82 ± 18 percent compared with 55 ± 18 percent without Brava (p < 0.00001). There was a strong linear correlation (R = 0.87) between pregrafting Brava expansion and the resultant breast augmentation. There were no suspicious breast masses or nodules. Magnetic resonance imaging recognized a 16 percent incidence of fat necrosis easily identified at 1-year mammographic evaluation.
CONCLUSION:
: The addition of Brava expansion before autologous fat grafting leads to significantly larger breast augmentations, with more fat graft placement, higher graft survival rates, and minimal graft necrosis or complications, demonstrating high safety and efficacy for the procedure
RESULTS:
Breast volume was unchanged between 3 and 6 months. Seventy-one of the treated women were compliant with Brava wear and had a mean augmentation volume at 12 months of 233 ml per breast compared with 134 ml per breast in published series without Brava (p < 0.00001). Graft survival was 82 ± 18 percent compared with 55 ± 18 percent without Brava (p < 0.00001). There was a strong linear correlation (R = 0.87) between pregrafting Brava expansion and the resultant breast augmentation. There were no suspicious breast masses or nodules. Magnetic resonance imaging recognized a 16 percent incidence of fat necrosis easily identified at 1-year mammographic evaluation.
CONCLUSION:
: The addition of Brava expansion before autologous fat grafting leads to significantly larger breast augmentations, with more fat graft placement, higher graft survival rates, and minimal graft necrosis or complications, demonstrating high safety and efficacy for the procedure